Since the introduction of novel therapeutic agents including thalidomide, lenalidomide and bortezomib, the prognosis of multiple myeloma (MM) has significantly improved. These agents have been incorporated into numerous treatment schedules for newly diagnosed as well as more advanced MM patients. Hence, the therapeutic options for MM have become more complex and subject to rapid changes. The multiple myeloma study group (MMSG) of the Belgian Hematological Society has established recommendations for the treatment of MM as based on an extensive review of the literature which is also summarized in this paper. The recommendations are the result of a consensus opinion between haematologists with experience in the field and representing most haematology centres in Belgium. Where applicable, reimbursement criteria are also taken into account. The consensus recommendations should be a reference for use by clinical haematologists in daily practice.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1179/acb.2010.055 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Mechanisms for resistance to BCMA-targeted immunotherapies in multiple myeloma.
Blood Rev
January 2025
Department of Hematology, First Hospital of Jilin University, Changchun, Jilin, China. Electronic address:
Multiple myeloma (MM) remains incurable and patients eventually face the relapse/refractory dilemma. B cell maturation antigen (BCMA)-targeted immunotherapeutic approaches have shown great effectiveness in patients with relapsed/refractory MM, mainly including chimeric antigen receptor T cells (CAR-T), bispecific T cell engagers (TCEs), and antibody-drug conjugates (ADCs). However, their impact on long-term survival remains to be determined.
View Article and Find Full Text PDFTyrosine Kinase Inhibitor Treatment Patterns in Patients With Chronic-Phase Chronic Myeloid Leukemia: A Single Center Data From China.
Clin Lymphoma Myeloma Leuk
December 2024
Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China; Hematology Center, Peking University People's Hospital, Qingdao, China. Electronic address:
Aim: To describe tyrosine kinase inhibitor (TKI) treatment patterns and analyze co-variates of TKI switch for chronic myeloid leukemia (CML) patients in a center from China.
Methods: A retrospectively study was designed to analyze TKI switching patterns, reasons and associated covariates in patients with CP-CML.
Results: 1766 patients receiving initial imatinib (n = 1374), nilotinib (n = 254), dasatinib (n = 63) and flumatinib (n = 75) therapy were retrospectively interrogated.
Identifying potential prognosis markers in relapsed multiple myeloma via integrated bioinformatics analysis and biological experiments.
Curr Res Transl Med
January 2025
Department of Hematology, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing, China. Electronic address:
Background: Almost all multiple myeloma (MM) patients will eventually develop disease that has relapsed with or become refractory to current therapeutic regimes. However, the pervious clinical parameters have been proved inaccurate for defining MM relapse, and molecular targets have become the focuses of interests. Prognostic predictions based on molecular targets have been more effective to this day.
View Article and Find Full Text PDFPredictive Role of Soluble B-Cell Maturation Antigen in Short-Term Monitoring of Differently Treated Multiple Myeloma Patients: A Prospective Study.
J Clin Lab Anal
January 2025
Hematology Division, Pisa University Hospital, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Background: The management of multiple myeloma is challenging because the disease is incurable and unexpected relapses can threaten a patient's survival. Several assessment systems are currently available, but they often require invasive or costly procedures (e.g.
View Article and Find Full Text PDFand coinfection in a patient with multiple myeloma: Case report.
Heliyon
January 2025
Lithuanian University of Health Sciences, Faculty of Medicine, A.Mickeviciaus street, 9, LT-44307, Kaunas, Lithuania.
Introduction: is a formidable pathogen that poses a significant threat to immunocompromised and might cause rare atypical forms of the disease especially complicated with coinfection.
Case: We present a case of a patient with meningoencephalitis, endocarditis, sepsis, and osteomyelitis, highlighting the complexities of managing disseminated polymicrobial infection. A 64-year-old female with multiple myeloma treated with chemotherapy presented with fever, altered mental status, nausea, and diarrhea to the emergency department.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!